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Introduction
The development of monoclonal antibody (mAb) pro-
cesses conventionally involves the generation of multiple
cell lines in multiwell plates, cell line screening in shake
flasks followed by final cell line selection and process
optimisation in bioreactors. This process can typically
take up to 18 months to generate a robust process suita-
ble for early phase manufacturing and therefore any
opportunity to streamline this process impacts directly
on drug development timelines.
This work describes the potential integration of the
Micro-24 Bioreactor system (Pall Life Sciences) and the
Duetz Microflask system (Applikon Biotechnology) into
cell line development and early process development
and demonstrates how these systems can be used for
cell line evaluation and process optimisation. The
Micro-24 Bioreactor system comprises 24 bioreactors
(7ml working volume) each capable of independent tem-
perature, dissolved oxygen and pH control. Cell cultures
are carried out in a presterilised polycarbonate mamma-
lian cell culture cassette with a central vent and are
inoculated manually in a laminar flow cabinet before
sealing with Type A single use closures and incubation
under experimental conditions.
Methods
The performance of a number of cell lines in the Micro-
24 Bioreactor and the Duetz Microflask system was
compared to that in shake flasks and bioreactors using
cell numbers, viability and product titre. This data was
then used to rank cell lines according to specific para-
meters. Unless otherwise stated a standard hydrolysate
containing complex medium and standard experimental
conditions were used throughout this work. For shake
flasks these were: 35°C, 5% CO2, 140 rpm; for Duetz
Microflasks: 35°C, 5% CO2, 200 rpm, 80% humidity and
for Micro-24 Bioreactors: 35°C, 650rpm, 6.95 pH, 30%
DO. Viable cell numbers and viability were determined
using a ViCell Cell Viability Analyser (Beckman Coulter)
and antibody titres were determined using an Immuno-
chemistry System (Beckman Coulter).
Reproducibility
A hydrolysate containing complex media fed batch pro-
cess was run in each of the 24 bioreactors using the
same model CHO cell line. Viable cell numbers (VCC),
viability and titre were measured in each bioreactor and
the coefficients of variation (CV) were calculated for
each time point. This data was also used to calculate the
specific productivity (SPR) for each bioreactor. At each
time point CVs were generally less than 10% for each
parameter measured and there was no significant differ-
ence between different rows of the cassette.
Cell Line Selection
To demonstrate the potential of this system to identify
candidate mAb producing cell lines a series of experi-
ments was carried out using the Micro-24 Bioreactor
s y s t e ma n dt h er e s u l t sc o m p a r e dt ot h o s eo b t a i n e di n
our standard cell line selection process. After initial
screening in static multiwell plates during scale up a
further screen in the Duetz Microflask system indicated
significant differences in the performance of the
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taining batch process peak titres varied by up to 60%
a n dt h e r ew a sa2f o l dd i f f e r e n c ei nt h eo v e r a l lS P R
across the different cell lines.
Based on titre and SPR data from the Duetz Micro-
flask screen 12 of these cell lines were selected for
further evaluation. Using the standard batch process
conditions these cell lines were grown in parallel in the
Micro-24 Bioreactors, Duetz Microflasks and conven-
tional shake flasks. Although there were some differ-
ences in absolute titres the rank order of cell lines was
similar in each of the systems tested here (Figure 1a and
b) with R
2=0.66 (Micro-24 v Duetz) and R
2=0.72
(Micro-24 v shake flasks).The rank order of peak VCC
was also similar in the Micro-24 and shake flasks (R
2 =
0.7) although there was less similarity in overall SPR (R
2
= 0.4).
This data from the batch process was used to select 6
cell lines for evaluation in the standard fed batch pro-
cess which was run in parallel in the Micro-24 Bioreac-
tor and shake flasks.
For each cell line the effect of feeding was similar in
Micro-24 Bioreactors to shake flasks (Figure 1C) and
the rank orders of titre, VCC and SPR achieved in the
Micro-24 Bioreactors were similar to those achieved in
shake flasks (Figure 1D, E and F).
Bioreactor validation
Clones ranked 1, 2, 5 and 12 in the Micro-24 Bioreac-
tors were tested in conventional 2 litre bioreactors. In
bioreactors the titre produced by the top ranked clone
was approximately 20% higher than the clone ranked 12.
The remaining 2 clones (ranked 2 and 5 in the Micro-
24) produced intermediate titres.
Product quality
SEC, CE-IEF and NGHC data for the mAb produced in
the Micro-24 showed no significant differences to that
produced in control shake flasks.
Process optimization
The Micro-24 Bioreactor also enables early stage pro-
cess optimisation to be carried out at a small scale. The
potential for media development is shown by the data in
Table 1A which demonstrates that the same trend in
peak titres is observed when cells are grown in 4 differ-
ent media in shake flasks, conventional bioreactors and
the Micro-24. Similarly a further experiment in the
Micro-24 Bioreactor to investigate the effect of pH and
temperature stepdown on performance demonstrated
that condition dependent titre improvements could be
identified using this instrument (Table 1B).
Discussion
This data demonstrates that the Micro-24 Bioreactor
can be used successfully to select high producing cell
lines and to carry out initial process optimisation experi-
ments. Although there were some differences in abso-
lute data the rank orders and process trends identified
in the Micro-24 Bioreactors were similar to those in
conventional systems. Therefore this work has shown
that the Micro-24 Bioreactor system could be used to
replace shake flasks and bioreactors in cell line evalua-
tion and early process improvement work.
Figure 1 Comparison of performance rank order of clones in different bioreactor systems in a hydrolysate containing medium batch process
(Figure 1A and B) and fed batch process (Figure 1C, 1D, 1E and 1F).
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Table 1 Process optimization.
Table 1A – Medium Development
Medium Shake flasks
(120mL)
Bioreactor
(2000mL)
Micro-24
(7mL)
Medium 1 100% 100% 100%
Medium 2 129% 125% 124%
Medium 3 121% 131% 140%
Medium 4 153% 175% 159%
Table 1B – Condition Optimisation
pH Temperature Relative titre
Condition
1
High Low 58%
Condition
2
High High 100%
Condition
3
Low Low 96%
Condition
4
Low High 141%
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